SG
DFTX

Sankala Group’s Definium Therapeutics DFTX Stock Holding History

Sankala Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.43K Hold
141
– – ﹤0.01% 446
2026
Q1 		$2.56K Sell
141
-250
-64% -$4.24K ﹤0.01% 475
2025
Q4 		$6.82K Buy
+391
New +$4.84K 0.01% 427

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sankala Group's DFTX Position: Q2 2026 in Review

Sankala Group held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 141 shares worth $6.43K. The position accounts for ﹤0.01% of the portfolio, ranked #446.

Sankala Group first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.82K in Q4 2025. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Sankala Group held 141 shares of Definium Therapeutics worth $6.43K as of Q2 2026.
  • Sankala Group left its Definium Therapeutics share count unchanged in Q2 2026.
  • Definium Therapeutics made up ﹤0.01% of Sankala Group's portfolio in Q2 2026, its #446 holding.
  • Sankala Group first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Sankala Group's Definium Therapeutics position peaked at $6.82K in Q4 2025.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.